Quick Links: Skip to main page content
Skip to Search
Skip to Topics Menu
Skip to Common Links
U.S. Food & Drug Administration
Follow FDA
En Español
Search FDA
Home
Food
Drugs
Medical Devices
Radiation-Emitting Products
Vaccines, Blood & Biologics
Animal & Veterinary
Cosmetics
Tobacco Products
New Pediatric Labeling Information Database - Detail
FDA Home
Pediatrics
New Pediatric Labeling Information Database
Detail
-
Please note:
JavaScript must be enabled for this application to work properly.
Check your settings
if you are unsure if your JavaScript is enabled.
Pediatric Labeling Date:
07/29/2008
Trade Name:
Cancidas
Generic Name or Proper Name (*):
caspofungin
Indications Studied:
Empirical therapy for presumed fungal infections in febrile, neutropenic patients; Candidemia and certain Candida infections; Esophageal Candidiasis; Invasive Aspergillosis in patients who are refractory to or intolerant of other therapies
Label Changes Summary:
Extended indication from adults to children 3 months and older based upon evidence from adequate and well-controlled studies in adults and PK data in pediatric patients and additional data from pediatric studies The efficacy and safety have not been adequately studied in infants < 3 months The ability of caspofungin to penetrate the blood-brain barrier and to treat patients with meningitis and endocarditis is unknown Dosing should be based on the patients body surface area. Maximum loading dose and daily maintenance dose should not exceed 70 mg The safety profile in pediatrics is comparably to adults Information on dose, Aes, PK parameters, clinical studies and infusion preparation instructions
Product Labeling:
Labeling
BPCA(B) and PREA(P):
B, P
Sponsor:
Merck
Pediatric Exclusivity Granted Date:
04/15/2008
NNPS:
FALSE'
Therapeutic Category:
Antifungal
-
-